

³⁴⁶ Efficacy and Safety of Sacral Neuromodulation with **InterStim™ II in Patients with Neurogenic Bladder and/or Bowel**



Omri Schwarztuch Gildor MD, Michael Vainrib MD Meir Medical Center, Kfar-Saba, Israel

INTRODUCTION

- Neurogenic bladder is a term used to describe lower urinary tract dysfunction resulting from a wide group of neurologic diseases.
- Several options for treatment are available, however, choosing the right treatment for each patient can be challenging.
- According to international guidelines, Sacral Neuromodulation (SNM) is an alternative surgical option for the • treatment of medical refractory neurogenic bladder and/or bowel.
- It is not clear which patients are likely to benefit from SNM implantation.

OBJECTIVES

- Compare the efficacy and the safety of SNM in neurogenic patients to non-neurogenic (idiopathic) patients.
- Identify patients with neurogenic conditions who most likely could benefit from SNM, and better understand its ۲ prospects and limitations in this population.

MATERIALS AND METHODS


- Retrospective single center chart review of patients who were admitted for InterStim[™]II implantation between 2017-2021.
- **Indications for SNM:**

Fecal ± Urinary incontinence

refractory urge incontinence

- **Group 1 = neurogenic** patients **Group 2 = idiopathic** patients
- **Successful outcome** was defined by **at least 50% improvement** in symptoms documented in the patients' diaries.

 frequency/urgency non-obstructing urinary retention (NOUR) fecal incontinence <u>Inclusion criteria</u> – all patients who completed: evaluation diary one week prior to, two weeks of advanced evaluation follow-up of at least 6 weeks after SNM 	 <u>Adverse outcomes</u>: revision surgeries, removal of InterStim[™]II etc. <u>Categorical and continuous variables were analyzed</u> by chi-square/Fisher exact and t-student tests, appropriately. Kaplan-Meier analysis was performed to compare the time from SNM implantation till InterStim[™]II removal between study groups.
RESULTS	
 57 patients [mean age of 62.07±15.91 y.o.] (Table 1) Neurogenic patients' etiologies: Discopathy or spinal stenosis = 7 Multiple Sclerosis = 3, Parkinson's disease = 2, Partial sacral agenesis = 1, Low anterior resection syndrome = 1. Most patients are females (64%) Most frequent indication for a surgery – NOUR (79%) 	 No significant difference between study groups in (Table 1/Figure 1): Demographic characteristics Surgery duration Successful advanced evaluation Median follow-up after SNM implantation Number of follow-up outpatient clinic visits for a regular checkup and/or a troubleshooting Long-term success rate Time to InterStim[™]II removal
Group 1 Group 2 Neurogenic Idiopathic n=14 n=43 Patient demographics 9 (64%) 29 (67%) p=1 Age (years) 62.43±14.18 61.95±16.59 p=0.918 Indication (n, %) p=0.515 Non-obstructive urinary retention 11 (79%) 27 (63%)	Figure 1: Time from SNM implantation to InterStim [™] II removal during the follow-up



CONCLUSIONS

0.6

• SNM is a safe procedure in neurogenic patients with a similar rate of adverse events.

15 (35%)

• Patients with **neurogenic bladder and/or bowel** who are refractory to the conservative treatments could benefit from SNM with a **similar success rate**.

• SNM could be offered in selected neurogenic patients.

3 (21%)